IONQ expands quantum reach with UMD, Cambridge and Chicago deals, boosting networking, hardware and commercialization across global research hubs.
IonQ Inc (NYSE: IONQ) is pushing meaningfully higher on Apr. 14 after the quantum-technology company announced two major technical and commercial milestones. As investors cheered the news, IONQ broke above its 20-day and 50-day moving averages (MAs), indicating a shift in near-term momentum in favour of the bulls.
Quantum computing stocks are surging in midday trading on Tuesday, with the sector's three most-watched pure-plays all posting double-digit gains.
IonQ (IONQ) stands out as a leading quantum platform, surpassing $100 million in annual revenue and demonstrating strong operational and technological momentum. IONQ's networking capabilities and integration of quantum memory and photonic interconnects position it for scalable, networked quantum computing leadership. Despite a 34x forward revenue multiple and ongoing EBITDA losses, IONQ's robust liquidity and R&D focus support its aggressive growth trajectory.
IonQ, Inc. (IONQ) closed at $28.49 in the latest trading session, marking a -2.56% move from the prior day.
IONQ boosts its defense and aerospace role with major US contracts, partnerships and a $151B SHIELD program win, signaling rising quantum tech influence.
Zacks.com users have recently been watching IonQ (IONQ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
IonQ (NYSE:IONQ | IONQ Price Prediction) trades at $27.79 as of writing.
In the closing of the recent trading day, IonQ, Inc. (IONQ) stood at $27.79, denoting a -3.61% move from the preceding trading day.
IonQ (IONQ) reported earnings 30 days ago. What's next for the stock?
IonQ targets $225-$245M 2026 revenues as backlog jumps to $370M, fueled by a strong balance sheet and plans for a 256-qubit quantum system.
IonQ's 2025 results met the expectations set in my previous article. Models updated to estimate 2026 and 2027 revenues. Created 5-year financial projection up to 2030.